Literature DB >> 35462085

Medical and Surgical Care of Patients With Mesothelioma and Their Relatives Carrying Germline BAP1 Mutations.

Michele Carbone1, Harvey I Pass2, Guntulu Ak3, H Richard Alexander4, Paul Baas5, Francine Baumann6, Andrew M Blakely7, Raphael Bueno8, Aleksandra Bzura9, Giuseppe Cardillo10, Jane E Churpek11, Irma Dianzani12, Assunta De Rienzo8, Mitsuru Emi13, Salih Emri14, Emanuela Felley-Bosco15, Dean A Fennell9, Raja M Flores16, Federica Grosso17, Nicholas K Hayward18, Mary Hesdorffer19, Chuong D Hoang20, Peter A Johansson18, Hedy L Kindler21, Muaiad Kittaneh22, Thomas Krausz23, Aaron Mansfield24, Muzaffer Metintas3, Michael Minaai6, Luciano Mutti25, Maartje Nielsen26, Kenneth O'Byrne27, Isabelle Opitz15, Sandra Pastorino6, Francesca Pentimalli28, Marc de Perrot29, Antonia Pritchard30, Robert Taylor Ripley31, Bruce Robinson32, Valerie Rusch33, Emanuela Taioli34, Yasutaka Takinishi6, Mika Tanji6, Anne S Tsao35, A Murat Tuncer36, Sebastian Walpole18, Andrea Wolf37, Haining Yang6, Yoshie Yoshikawa13, Alicia Zolondick6, David S Schrump20, Raffit Hassan38.   

Abstract

The most common malignancies that develop in carriers of BAP1 germline mutations include diffuse malignant mesothelioma, uveal and cutaneous melanoma, renal cell carcinoma, and less frequently, breast cancer, several types of skin carcinomas, and other tumor types. Mesotheliomas in these patients are significantly less aggressive, and patients require a multidisciplinary approach that involves genetic counseling, medical genetics, pathology, surgical, medical, and radiation oncology expertise. Some BAP1 carriers have asymptomatic mesothelioma that can be followed by close clinical observation without apparent adverse outcomes: they may survive many years without therapy. Others may grow aggressively but very often respond to therapy. Detecting BAP1 germline mutations has, therefore, substantial medical, social, and economic impact. Close monitoring of these patients and their relatives is expected to result in prolonged life expectancy, improved quality of life, and being cost-effective. The co-authors of this paper are those who have published the vast majority of cases of mesothelioma occurring in patients carrying inactivating germline BAP1 mutations and who have studied the families affected by the BAP1 cancer syndrome for many years. This paper reports our experience. It is intended to be a source of information for all physicians who care for patients carrying germline BAP1 mutations. We discuss the clinical presentation, diagnostic and treatment challenges, and our recommendations of how to best care for these patients and their family members, including the potential economic and psychosocial impact.
Copyright © 2022 International Association for the Study of Lung Cancer. All rights reserved.

Entities:  

Keywords:  Asbestos; BAP1; Cancer genetics; Germline mutations; Mesothelioma; Tumor predisposition syndromes

Mesh:

Substances:

Year:  2022        PMID: 35462085      PMCID: PMC9233126          DOI: 10.1016/j.jtho.2022.03.014

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   20.121


  104 in total

Review 1.  A New Prognostic Score Supporting Treatment Allocation for Multimodality Therapy for Malignant Pleural Mesothelioma: A Review of 12 Years' Experience.

Authors:  Isabelle Opitz; Martina Friess; Peter Kestenholz; Didier Schneiter; Thomas Frauenfelder; Thi Dan Linh Nguyen-Kim; Burkhardt Seifert; Mir Alireza Hoda; Walter Klepetko; Rolf A Stahel; Walter Weder
Journal:  J Thorac Oncol       Date:  2015-11       Impact factor: 15.609

Review 2.  Malignant pleural mesothelioma: history, controversy and future of a manmade epidemic.

Authors:  Oluf Dimitri Røe; Giulia Maria Stella
Journal:  Eur Respir Rev       Date:  2015-03

3.  Functional Genomic Screen in Mesothelioma Reveals that Loss of Function of BRCA1-Associated Protein 1 Induces Chemoresistance to Ribonucleotide Reductase Inhibition.

Authors:  Agata Okonska; Saskja Bühler; Vasundhara Rao; Manuel Ronner; Maxime Blijlevens; Ida H van der Meulen-Muileman; Renee X de Menezes; Martin Wipplinger; Kathrin Oehl; Egbert F Smit; Walter Weder; Rolf A Stahel; Lorenza Penengo; Victor W van Beusechem; Emanuela Felley-Bosco
Journal:  Mol Cancer Ther       Date:  2019-10-16       Impact factor: 6.261

4.  Genomic events associated with progression of pleural malignant mesothelioma.

Authors:  Sergey V Ivanov; Jeremy Miller; Robert Lucito; Chunlao Tang; Alla V Ivanova; Jianming Pei; Michele Carbone; Christina Cruz; Amanda Beck; Craig Webb; Daisuke Nonaka; Joseph R Testa; Harvey I Pass
Journal:  Int J Cancer       Date:  2009-02-01       Impact factor: 7.396

5.  Sensitivity to asbestos is increased in patients with mesothelioma and pathogenic germline variants in BAP1 or other DNA repair genes.

Authors:  Marta Betti; Anna Aspesi; Daniela Ferrante; Marika Sculco; Luisella Righi; Dario Mirabelli; Francesca Napoli; Milena Rondón-Lagos; Elisabetta Casalone; Francesca Vignolo Lutati; Paola Ogliara; Paolo Bironzo; C Laura Gironi; Paola Savoia; Antonella Maffè; Silvana Ungari; Federica Grosso; Roberta Libener; Renzo Boldorini; Michele Valiante; Barbara Pasini; Giuseppe Matullo; Giorgio Scagliotti; Corrado Magnani; Irma Dianzani
Journal:  Genes Chromosomes Cancer       Date:  2018-11       Impact factor: 5.006

6.  BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs.

Authors:  Michele Carbone; Laura Korb Ferris; Francine Baumann; Andrea Napolitano; Christopher A Lum; Erin G Flores; Giovanni Gaudino; Amy Powers; Peter Bryant-Greenwood; Thomas Krausz; Elizabeth Hyjek; Rachael Tate; Joseph Friedberg; Tracey Weigel; Harvey I Pass; Haining Yang
Journal:  J Transl Med       Date:  2012-08-30       Impact factor: 5.531

7.  Onconase mediated NFKβ downregulation in malignant pleural mesothelioma.

Authors:  C M Goparaju; J D Blasberg; S Volinia; J Palatini; S Ivanov; J S Donington; C Croce; M Carbone; H Yang; H I Pass
Journal:  Oncogene       Date:  2011-02-14       Impact factor: 9.867

8.  Psychosocial consequences of allocation to lung cancer screening: a randomised controlled trial.

Authors:  Louise Mosborg Aggestrup; Mie Sara Hestbech; Volkert Siersma; Jesper Holst Pedersen; John Brodersen
Journal:  BMJ Open       Date:  2012-03-01       Impact factor: 2.692

Review 9.  Exhaled Breath Analysis in Diagnosis of Malignant Pleural Mesothelioma: Systematic Review.

Authors:  Zehra Nur Töreyin; Manosij Ghosh; Özlem Göksel; Tuncay Göksel; Lode Godderis
Journal:  Int J Environ Res Public Health       Date:  2020-02-10       Impact factor: 3.390

10.  Prediagnostic detection of mesothelioma by circulating calretinin and mesothelin - a case-control comparison nested into a prospective cohort of asbestos-exposed workers.

Authors:  Georg Johnen; Katarzyna Burek; Irina Raiko; Katharina Wichert; Beate Pesch; Daniel G Weber; Martin Lehnert; Swaantje Casjens; Olaf Hagemeyer; Dirk Taeger; Thomas Brüning
Journal:  Sci Rep       Date:  2018-09-25       Impact factor: 4.379

View more
  4 in total

1.  Analysis of uveal melanomas and paired constitutional DNA for exclusion of a BAP1-tumor predisposition syndrome.

Authors:  Yasaman Arjmand Abbassi; Claudia Le Guin; Norbert Bornfeld; Nikolaos E Bechrakis; Michael Zeschnigk; Dietmar R Lohmann
Journal:  Fam Cancer       Date:  2022-08-03       Impact factor: 2.446

2.  Bilateral Pleural Mesothelioma In Situ and Peritoneal Mesothelioma In Situ Associated With BAP1 Germline Mutation: A Case Report.

Authors:  Alyssa MacLean; Andrew Churg; Scott Thomas Johnson
Journal:  JTO Clin Res Rep       Date:  2022-06-14

3.  Case report: Mesothelioma and BAP1 tumor predisposition syndrome: Implications for public health.

Authors:  Luigi Vimercati; Domenica Cavone; Francesco Fortarezza; Maria Celeste Delfino; Romina Ficarella; Angela Gentile; Angela De Palma; Giuseppe Marulli; Luigi De Maria; Concetta Caporusso; Andrea Marzullo; Antonio d'Amati; Daniele Egidio Romano; Antonio Caputi; Stefania Sponselli; Gabriella Serio; Federica Pezzuto
Journal:  Front Oncol       Date:  2022-08-04       Impact factor: 5.738

4.  Diagnostics of BAP1-Tumor Predisposition Syndrome by a Multitesting Approach: A Ten-Year-Long Experience.

Authors:  Marika Sculco; Marta La Vecchia; Anna Aspesi; Michela Giulia Clavenna; Michela Salvo; Giulia Borgonovi; Alessandra Pittaro; Gianluca Witel; Francesca Napoli; Angela Listì; Federica Grosso; Roberta Libener; Antonio Maconi; Ottavio Rena; Renzo Boldorini; Daniela Giachino; Paolo Bironzo; Antonella Maffè; Greta Alì; Lisa Elefanti; Chiara Menin; Luisella Righi; Cristian Tampieri; Giorgio Vittorio Scagliotti; Caterina Dianzani; Daniela Ferrante; Enrica Migliore; Corrado Magnani; Dario Mirabelli; Giuseppe Matullo; Irma Dianzani
Journal:  Diagnostics (Basel)       Date:  2022-07-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.